Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048593 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
A Phase 2 study, sponsored by ICON Bioscience.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01048593: Clinical Trial Phase 2 study, sponsored by ICON Bioscience.
NCT01048593 is a Phase 2 study that was terminated before completion, run by ICON Bioscience. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01048593, a Phase 2 study, was terminated before completion, sponsored by ICON Bioscience.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
Primary Outcome
Efficacy was assessed by slit lamp biomicroscopy to evaluate the anterior chamber cells (ACC) graded on a scale of 0 to 4. The primary efficacy endpoint was complete clearing of ACC, where grade 0 = 0 cells in the anterior chamber on POD 8.
Interventions
- DRUG IBI-10090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Why NCT01048593 stopped before completion
NCT01048593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which IBI-10090 is the first listed.
NCT01048593 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01048593 about?
NCT01048593 is a clinical study titled "Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery". This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
What is the current status of trial NCT01048593?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01048593?
The interventions under investigation include: IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT01048593?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01048593's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia